# Grace Therapeutics, Inc. (GRCE)

> Source: Nexqual · https://nexqual.com/GRCE · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, Grace Therapeutics, Inc. (GRCE), nexqual.com/GRCE" · informational, not investment advice.

**Price:** USD 1.95 (+3.17% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 1.89 · day 1.89–1.97 · 52w 1.79–5.18 · market cap $41.0M · NCM

## Key facts
- Analysts: Buy (mean 2.00 on a 1–5 scale) (2 analysts), mean target USD 5.88 (range 3.91–7.85).
- Total return with dividends: 1Y -39.3% vs S&P 500 +18.1%; 5Y -81.3% vs S&P 500 +85.1%.

## Analysts
Consensus Buy (mean 2.00 on a 1–5 scale), 2 analysts; mean target USD 5.88 (low 3.91, high 7.85).

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2021-10-11) |
|---|---|---|
| Total return | -39.3% | -81.3% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -39.4% | -28.4% |
| Volatility (annualized) | 82.5% | 73.5% |
| Max drawdown | -63.2% (Apr 2026→Oct 2026) | -83.0% (Oct 2021→Sep 2023) |

## Peers (Biotechnology)
RYTM (Rhythm Pharmaceuticals, Inc.) USD 87.97 +1.57% · BLTE (Belite Bio, Inc) USD 152.62 +0.49% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.72 +1.52% · PRAX (Praxis Precision Medicines, Inc) USD 248.24 +2.01% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.12 +4.11% · SYRE (Spyre Therapeutics, Inc.) USD 80.1 -0.44%

## More
Full page: https://nexqual.com/GRCE · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt